Content about Analgesics

WASHINGTON Johnson & Johnson said Wednesday that it plans to ship limited quantities of one of its children's medicines following a nationwide recall.

CHADDS FORD, Pa. The Food and Drug Administration has granted priority review to an opioid painkiller designed to thwart drug abusers.

Endo Pharmaceuticals said Wednesday that the FDA would expedite review of its new oral formulation of long-acting oxymorphone, which is designed to be crush-resistant. The FDA expects to take action on the drug in early January.

WASHINGTON House Committee on Oversight and Government Reform chairman Ed Towns, D-N.Y., on Thursday announced that the committee will hold a hearing Sept. 30 at 10 a.m. to examine the circumstances surrounding Johnson & Johnson’s recall of more than 135 million bottles of infant and children’s medicines produced by Johnson & Johnson/McNeil Consumer Healthcare, including children’s Tylenol, infant’s Tylenol, children’s Motrin and children’s Benadryl.

RICHMOND, Va. The Food and Drug Administration has approved Reckitt Benckiser’s treatment for opioid addiction, Reckitt Benckiser said.

The drug maker announced the approval of Suboxone (buprenorphine and naloxone), a drug delivered through a fast-dissolving film placed under the tongue. The film is based on a technology known as PharmFilm, made by MonoSol Rx.

PHILADELPHIA According to a study released by the Relational Capital Group, despite product recalls and a plant closure, consumer purchase intent and brand loyalty for Tylenol still currently exceeds that of Advil.

CARY, N.C. Generic drug maker Cornerstone Therapeutics has filed for approval of a treatment for cold symptoms, Cornerstone said Thursday.

The drug maker announced the filing of an application with the Food and Drug Administration for CRTX-067 (chlorpheniramine polistirex and hydrocodone polistirex) oral suspension, a generic version of UCB’s Tussionex.

ROCKVILLE, Md. Note to the Food and Drug Administration from the chain pharmacy industry: when it comes to beefing up oversight and regulation of some high-risk medications, slow and steady is the best approach.

PITTSBURGH The Food and Drug Administration has approved a generic arthritis treatment made by Mylan, the drug maker said Wednesday.

The FDA approved nabumetone tablets, a treatment for osteoarthritis and rheumatoid arthritis, in the 500 mg and 750-mg strengths.